6533b7d8fe1ef96bd126a576

RESEARCH PRODUCT

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

Florian NolteMarkus P. RadsakCornelia S. SchmidtUwe PlatzbeckerWolf-karsten Hofmann

subject

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drug

description

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

yearjournalcountryeditionlanguage
2017-03-14European journal of haematology
10.1111/ejh.12883https://pubmed.ncbi.nlm.nih.gov/28321924